Global Infectious Disease Testing Products Market, By Product and Service (Assays, Kits, and Reagents, Instruments, Services and Software), Technology (Immunodiagnostics, Clinical Microbiology, Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing and Next-Generation Sequencing, DNA Microarray, Other Technologies), Disease Type (Hepatitis, Human Immunodeficiency Virus, Chlamydia Trachomatis Genital Infection and Gonorrhea, Hospital-Acquired Infections, Human Papillomavirus, Tuberculosis, Influenza, Others), End- Users (Hospital/Clinical Laboratories, Reference Laboratories, Physician Offices, Academic/Research Institutes, Other End Users) – Industry Trends and Forecast to 2029.
Infectious Disease Testing Products Market Analysis and Size
Disorders produced by organisms, such as bacteria, viruses, fungus, or parasites, are known as infectious diseases. Human bodies are home to various microbes and bacterias. In most cases, they are beneficial or even safe. But certain microbes have the potential to cause disease in specific situations. Some infectious diseases can transmit from one person to another and are considered contagious. Germs in the air, water, food, or soil can spread other infectious diseases. They can also spread by animals or vectors like biting insects.
Data Bridge Market Research analyses that the infectious disease testing products market which was USD 18.34 billion in 2021, would rocket up to USD 28.73 billion by 2029, and is expected to undergo a CAGR of 5.77% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Infectious Disease Testing Products Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product and Service (Assays, Kits, and Reagents, Instruments, Services and Software), Technology (Immunodiagnostics, Clinical Microbiology, Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing and Next-Generation Sequencing, DNA Microarray, Other Technologies), Disease Type (Hepatitis, Human Immunodeficiency Virus, Chlamydia Trachomatis Genital Infection and Gonorrhea, Hospital-Acquired Infections, Human Papillomavirus, Tuberculosis, Influenza, Others), End- Users (Hospital/Clinical Laboratories, Reference Laboratories, Physician Offices, Academic/Research Institutes, Other End Users)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott (U.S.), BD (U.S.), bioMérieux (France), Bio-Rad Laboratories Inc. (U.S.), Danaher (U.S.), DiaSorin S.p.A. (Italy), Meridian Bioscience Inc. (U.S.), Quidel Corporation (U.S.), Siemens (Germany), Thermo Fisher Scientific Inc. (U.S.), Johnson and Johnson Private Limited (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Cepheid (U.S.), Qiagen (Germany), OraSure Technologies, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
A chemluminescent immunoassay (ChLIA) is utilised for the qualitative detection of T. cruzi antibodies in human serum or plasma samples and is used to screen blood donors. An FDA-approved enzyme strip immunoassay (ESA) is utilised for confirmatory testing.
Infectious Disease Testing Products Market Dynamics
Drivers
- Increasing demand of personalised medicines
The development of genomics and proteomics is anticipated to boost market expansion. In the forecast period of 2022 to 2029, it is anticipated that additional factors such as rising government-funded programmes, rising shift from centralised laboratories to decentralised point-of-care testing, and rising demand for personalised medicines will boost the market for infectious disease testing products.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the market growth rate is the rising healthcare expenditure which helps improve its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding, which will further influence the market dynamics.
- Rise in the geriatric population
The rising prevalence rates of lifestyle disorders like rising health-care spending, and the fast-growing diagnostic industry are driving the infectious disease testing products market expansion. In addition, the growing elderly population, increased demand for laboratory automation, and more awareness of preventative healthcare are all driving the infectious disease testing products market forward.
Opportunities
- Increase in the number of research and development activities
The increased prevalence of infectious diseases around the world is what is driving the global market for infectious disease testing. Furthermore, the expansion of the market during the projected period is anticipated to be fuelled by investments in healthcare infrastructure made by governments all over the world. Additionally, it is expected that an increase in research and development activities in the healthcare industry will support market growth over the next years.
Restraints/Challenges
On the other hand, the unfavourable reimbursement policies, high healthcare cost limiting the use of novel diagnostic techniques and poor distribution channel will obstruct the market's growth rate.
This infectious disease testing products market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the infectious disease testing products market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Infectious Disease Testing Products Market
COVID-19 has led to the development of a number of novel, highly accurate, and cost-effective testing techniques. In order to assure the supply of testing kits in the healthcare industry, the Association of British HealthTech Industries (ABHI), BioIndustry Association (BIA), and the British In-Vitro Diagnostic Association (BIVDA) stated a global requirement for testing kit components on April 1, 2020. In order to determine who is affected by COVID-19, mass testing is carried out in South Korea. Additionally, lab tests are more accurate than testing kits. The producers are concentrating their efforts on creating sophisticated testing kits and using fresh approaches to save costs and win government approval.
Recent Development
- On March 18, 2020, The Food and Drug Administration (FDA) granted Abbott emergency use permission (EUA) for their molecular test to identify SARS-CoV-2, the virus that causes COVID-19. Approximately 150,000 laboratory tests will be conducted right away by the company.
- On March 31, 2020, Becton Dickinson and Company (BD) announced the release of a new Rapid Serology Test to identify COVID-19 exposure. The procedure is a new point-of-care test that can identify present or previous exposure to COVID-19 in less than 15 minutes by detecting antibodies in blood.
Global Infectious Disease Testing Products Market Scope
The infectious disease testing products market is segmented on the basis of product and services, technology, disease type, and end- users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product and Services
- Assays
- Kits
- Reagents
- Instruments
- Services and Software
Technology
- Immunodiagnostics
- Clinical Microbiology
- Polymerase Chain Reaction
- Isothermal Nucleic Acid Amplification Technology
- DNA Sequencing and Next-Generation Sequencing
- DNA Microarray
- Other Technologies
Disease Type
- Hepatitis
- Human Immunodeficiency Virus
- Chlamydia Trachomatis Genital Infection and Gonorrhea
- Hospital-Acquired Infections
- Human Papillomavirus
- Tuberculosis
- Influenza
- Others
End-User
- Hospitals/clinical laboratories
- Reference laboratories
- Physician offices
- Academic/research institutes
- Other end-users
Infectious Disease Testing Products Market Regional Analysis/Insights
The infectious disease testing products market is analysed and market size insights and trends are provided by country, product and services, technology, disease type, and end- users as referenced above.
The countries covered in the infectious disease testing products market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the infectious disease testing products market due to the growing number of geriatric population along with adoption of innovative medical technology.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising health awareness among the people and growing demand of advanced medical technology.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Infectious Disease Testing Products Market Share Analysis
The infectious disease testing products market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to infectious disease testing products market.
Some of the major players operating in the infectious disease testing products market are:
- Abbott (U.S.)
- BD (U.S.)
- bioMérieux (France)
- Bio-Rad Laboratories Inc. (U.S.)
- Danaher (U.S.)
- DiaSorin S.p.A. (Italy)
- Meridian Bioscience Inc. (U.S.)
- Quidel Corporation (U.S.)
- Siemens (Germany)
- Thermo Fisher Scientific Inc. (U.S.)
- Johnson and Johnson Private Limited (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Cepheid (U.S.)
- Qiagen (Germany)
- OraSure Technologies, Inc. (U.S.)
SKU-